The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global theranostics market reached a value of US$ XX Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Theranostics is a combination of various radioactive drugs and techniques used to diagnose, deliver therapy, and treat life-threatening illnesses. It is cost-effective and involves pharmacogenetics, proteomics, and biomarker profiling. It can be integrated with nanomedicine to target specific organs and tissues and improve patient-specific outcomes. Nowadays, researchers worldwide are developing new diagnostic and therapeutic agents for theranostics to personalize the treatment of cancer, reduce side effects of treatment, and improve the quality care of pharmacotherapy.
The rising prevalence of cancer due to the increasing consumption of tobacco and alcohol, high body mass index (BMI), low nutrition intake, and lack of physical activity represents one of the main factors stimulating the market growth. Moreover, according to the World Health Organization (WHO), cancer is the second leading cause of death globally, out of which 70% of deaths occur in low and middle-income countries. This is encouraging health and governing agencies of several countries to increase awareness about the available medical treatments and improve the healthcare infrastructure, which is positively influencing the market growth. The escalating demand for personalized medicine is also bolstering the market growth. Apart from this, the integration of seamless, multiple imaging treatment technologies within a single nanoparticle to tackle pathologies is driving the market. Furthermore, the increasing approvals to produce theranostics and rising investments in research and development (R&D) activities are other factors anticipated to propel the growth of the market in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global theranostics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on disease type, technology and end user.
Breakup by Disease Type:
Breakup by Technology:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc (Quest Diagnostics Incorporated), Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Myriad Genetics Inc., Pfizer Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Disease Type, Technology, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc (Quest Diagnostics Incorporated), Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Myriad Genetics Inc., Pfizer Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at